Description
A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).
Chemical properties
| Chemical formula | Net charge | Average mass |
|---|---|---|
| C11H15N5O5 | 0 | 297.26730 |
Nomenclature
| IUPAC | SMILES | InChI | InChIKey | Synonyms |
|---|---|---|---|---|
| 9-(beta-D-arabinofuranosyl)-6-methoxy-9H-purin-2-amine | COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O | InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1 | IXOXBSCIXZEQEQ-UHTZMRCNSA-N |
|
Citations
- Cohen, MH, et al. 2008. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. The Oncologist. 13(6).
- Commander, LA, et al. 2010. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. British Journal of Haematology. 150(3).
- Corrigan, DK, et al. 2010. Towards the development of a rapid, portable, surface enhanced Raman spectroscopy based cleaning verification system for the drug nelarabine. The Journal of Pharmacy and Pharmacology. 62(9).
- DeAngelo, DJ, et al. 2009. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematology/oncology Clinics of North America. 23(5).
- Gökbuget, N, et al. 2011. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 118(13).
- Homminga, I, et al. 2011. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. Blood. 118(8).
- Horibe, K, et al. 2011. [Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL]. [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology. 52(6).
- Horton, TM, et al. 2010. Educational paper. The development of new therapies for pediatric oncology. European Journal of Pediatrics. 170(5).
- Kesler, DF, et al. 1976. [Method of determination of the proteolytic activity with the aid of ninhydrin]. Laboratornoe Delo. (12).
- Narayanan, S, et al. 2011. Treatment of acute lymphoblastic leukemia in adults. Critical Reviews in Oncology/hematology. 81(1).
- Pham, A, et al. 2011. Precursor T-Cell acute lymphoblastic leukemia/lymphoma with rare presentation in the urinary bladder. Hematology Reports. 3(2).
- Reilly, KM, et al. 2009. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. OncoTargets and Therapy. 2.
- Robak, T, et al. 2011. New nucleoside analogs for patients with hematological malignancies. Expert Opinion On Investigational Drugs. 20(3).
- Roecker, AM, et al. 2010. Nelarabine in the treatment of refractory T-cell malignancies. Clinical Medicine Insights. Oncology. 4.
- Yamauchi, T, et al. 2010. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells. Oncology Reports. 23(2).